Cingulate Inc. (NASDAQ: CING) has amended its existing At-the-Market (ATM) sales agreement to add Maxim Group LLC as a sales agent. The company entered into Amendment No. 2 to the ATM Agreement with A.G.P./Alliance Global Partners and Maxim Group on November 13, 2026. The amendment allows Maxim to act as an agent alongside A.G.P. to sell the company's common stock, par value $0.0001 per share.
Under the original agreement, disclosed on March 24, 2026, Cingulate was authorized to offer and sell common stock with an aggregate offering price of up to $100,000,000. The company may offer and sell shares from time to time through the agents.
In addition to the financing update, Cingulate reported its financial results for the quarter ended September 30, 2026. The company announced that it has substantially completed manufacturing work required to address the U.S. Food and Drug Administration’s (FDA) chemistry, manufacturing, and controls (CMC) information requests for its lead asset, CTx-1301.
Cingulate expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027. The FDA issued a Complete Response Letter in June 2026 requesting additional CMC information, though the agency did not raise concerns regarding the clinical safety or efficacy of the drug.
As of September 30, 2026, Cingulate reported approximately $23.2 million in cash and cash equivalents, an increase from $11.0 million as of December 31, 2025. The company stated that its current cash and cash equivalents are sufficient to fund operations into mid-2027.
